Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
GK antisense RNA 1 (GK-AS1) is a long non-coding RNA (lncRNA) transcribed from the GK gene locus in antisense orientation. Its transcript is complementary to glycerol kinase mRNA and is classified as an antisense RNA. GK-AS1 does not code for a protein; instead, it is implicated in regulating the expression of GK and potentially other genes via transcriptional and epigenetic mechanisms. The clinical relevance of GK-AS1 is primarily associated with Glycerol kinase deficiency, a metabolic disorder. There is currently no evidence that GK-AS1 serves as a direct therapeutic target, nor are there approved drugs acting specifically on this lncRNA. Its broader biological and disease roles remain subjects of ongoing research.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on GK antisense RNA 1 (GK-AS1).